1)Cruccu G, et al:AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 15:1013-1028, 2008
2)Attal N, et al:EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision. Eur J Neurol 17:1113-e88, 2010 doi:10.1111/j.1468-1331.2010.02999.x
3)Bendtsen L, et al:European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 26:831-849
4)厚生労働行政推進調査事業費補助金(慢性の痛み政策研究事業)「慢性疼痛診療システムの均てん化と痛みセンター診療データベースの活用による医療向上を目指す研究」研究班(監),慢性疼痛診療ガイドライン作成ワーキンググループ(編):慢性疼痛診療ガイドライン.真興交易(株)医書出版部,東京,2021
5)日本神経学会,他(監),「頭痛の診療ガイドライン」作成委員会(編):頭痛の診療ガイドライン2021.医学書院,東京,2021
6)Lambru G, et al:Trigeminal neuralgia:a practical guide. Pract Neurol 21:392-402, 2021
7)Taylor JC, et al:Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 57:16-18, 1981
8)Wiffen PJ, et al:Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014:CD005451, 2014 doi:10.1002/14651858.CD005451.pub3
3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20:1034-1041, 2011
31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol 75:842-849, 2018
11)Steiner TJ, et al:Aids to management of headache disorders in primary care(2nd edition):on behalf of the European Headache Federation and Lifting The Burden:the Global Campaign against Headache. J Headache Pain 20:57, 2019 doi:10.1186/s10194-018-0899-2
12)Fromm GH, et al:Baclofen in the treatment of trigeminal neuralgia:double-blind study and long-term follow-up. Ann Neurol 15:240-244, 1984
13)Zhang J, et al:Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev:CD004029, 2013 doi:10.1002/14651858.CD004029.pub4
14)Mockenhaupt M, et al:Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64:1134-1138, 2005
15)Stavropoulou E, et al:The effect of intravenous lidocaine on trigeminal neuralgia:a randomized double blind placebo controlled trial. ISRN Pain 2014:853826, 2014 doi:10.1155/2014/853826
16)Kanai A, et al:Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth 97:559-563, 2006
17)Niki Y, et al:Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain Med 15:826-831, 2014
18)Wei J, et al:The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain:a meta-analysis of randomized controlled trials. Brain Behav 9:e01409, 2019 doi:10.1002/brb3.1409
19)波多野正和,池田匡志:精神科領域の薬理遺伝学.医のあゆみ283:701-704, 2022
20)Milosavljevic F, et al:Association of CYP2C19 and CYP2D6 Poor and intermediate metabolizer status with antidepressant and antipsychotic exposure:a systematic review and meta-analysis. JAMA Psychiatry 78:270-280, 2021